M.E. Olmedo

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 462 citations

Medicine, Oncology, Pharmacology +9

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro et al. · The Lancet Respiratory Medicine · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +11

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Emiliano Calvo, Víctor Moreno, Michael Flynn et al. · Annals of Oncology · 2017 · 85 citations · Full text

Medicine, Oncology, Pharmacology +12

SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

Manuel Dómine, Teresa Morán, Dolores Isla et al. · Clinical & Translational Oncology · 2020 · 60 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update

Afshin Dowlati, Horst-Dieter Hummel, Stéphane Champiat et al. · Journal of Clinical Oncology · 2024 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17